Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors

Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Sean, Spear, Ella, Sane, Nikhita, Nelson, Adam J., Nerlekar, Nitesh, Segelov, Eva, Nicholls, Stephen J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632129/
https://www.ncbi.nlm.nih.gov/pubmed/37076569
http://dx.doi.org/10.1038/s41371-023-00831-z
_version_ 1785132511973605376
author Tan, Sean
Spear, Ella
Sane, Nikhita
Nelson, Adam J.
Nerlekar, Nitesh
Segelov, Eva
Nicholls, Stephen J.
author_facet Tan, Sean
Spear, Ella
Sane, Nikhita
Nelson, Adam J.
Nerlekar, Nitesh
Segelov, Eva
Nicholls, Stephen J.
author_sort Tan, Sean
collection PubMed
description Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not assessed temporally to screen and monitor hypertension, which could independently increase the risk of ASCVD in cancer survivorship. This study reports the feasibility of using serial BP measurements from routine visits to day oncology center to diagnose and monitor hypertension control in cancer patients receiving ICIs. [Image: see text]
format Online
Article
Text
id pubmed-10632129
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106321292023-11-10 Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors Tan, Sean Spear, Ella Sane, Nikhita Nelson, Adam J. Nerlekar, Nitesh Segelov, Eva Nicholls, Stephen J. J Hum Hypertens Letter Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not assessed temporally to screen and monitor hypertension, which could independently increase the risk of ASCVD in cancer survivorship. This study reports the feasibility of using serial BP measurements from routine visits to day oncology center to diagnose and monitor hypertension control in cancer patients receiving ICIs. [Image: see text] Nature Publishing Group UK 2023-04-19 2023 /pmc/articles/PMC10632129/ /pubmed/37076569 http://dx.doi.org/10.1038/s41371-023-00831-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Letter
Tan, Sean
Spear, Ella
Sane, Nikhita
Nelson, Adam J.
Nerlekar, Nitesh
Segelov, Eva
Nicholls, Stephen J.
Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors
title Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors
title_full Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors
title_fullStr Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors
title_full_unstemmed Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors
title_short Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors
title_sort blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632129/
https://www.ncbi.nlm.nih.gov/pubmed/37076569
http://dx.doi.org/10.1038/s41371-023-00831-z
work_keys_str_mv AT tansean bloodpressuresurveillanceincancerpatientstreatedwithimmunecheckpointinhibitors
AT spearella bloodpressuresurveillanceincancerpatientstreatedwithimmunecheckpointinhibitors
AT sanenikhita bloodpressuresurveillanceincancerpatientstreatedwithimmunecheckpointinhibitors
AT nelsonadamj bloodpressuresurveillanceincancerpatientstreatedwithimmunecheckpointinhibitors
AT nerlekarnitesh bloodpressuresurveillanceincancerpatientstreatedwithimmunecheckpointinhibitors
AT segeloveva bloodpressuresurveillanceincancerpatientstreatedwithimmunecheckpointinhibitors
AT nichollsstephenj bloodpressuresurveillanceincancerpatientstreatedwithimmunecheckpointinhibitors

Ejemplares similares